Exploring future spinal cord injury therapies
Drug Target Review explores five of the latest research developments in the field of spinal cord injury (SCI) repair.
List view / Grid view
Drug Target Review explores five of the latest research developments in the field of spinal cord injury (SCI) repair.
Drug Target Review rounds up the latest updates on research into coronavirus treatments, focusing on virtual screening to find therapies for COVID-19.
A new microfluidic technology has been developed by researchers, which utilises magnetic ferrobots to automate chemical analyses and assays.
The first drug designed using artificial intelligence (AI) has moved into its Phase I trial. Professor Andrew Hopkins of Exscientia explains how an algorithm was used to achieve this milestone.
Dr Nicolas Poirier reveals how immunotherapies can be designed to recalibrate the immune system for long-term maintenance of autoimmune remission.
Drug Target Review spoke with CUE Biopharma’s President and CSO to find out how and why they created the ImmunoSTAT platform and the ways it may benefit drug design in the future.
Neuropathologic similarities between dolphins and humans suggest that the former could act as an effective model for the study of diseases such as Alzheimer’s. Professor Giovanni Di Guardo explains why dolphins could provide researchers with a new window into neurodegenerative conditons.
A collaborative team of researchers has discovered two molecules that target the melatonin receptor, responsible for regulating the circadian rhythm. This article delves into their study and its therapeutic relevance for the body clock.
A group of researchers, led by Professor Zucai Suo, have revealed the mode of action of two HIV drugs and identified how resistance can develop, which they say could lead to improved drug design in the future.
Here, the benefits of collaborating in drug discovery are explored through the strategic alliance between ELRIG and the British Pharmacological Society.
Drug Target Review explores research that suggests the microbiome could be a therapeutic target for major depressive disorder and what treatment options are now in the pipeline as a result of this association.
Researchers have developed a new body-on-chip technology that can demonstrate the pharmacokinetics and pharmacodynamics of drugs in a pre-clinical setting without the need for animal testing.
Drug Target Review explores the latest applications of stem cells in modelling disease, drug production and the most recent steps in regenerative medicine provided by research.
A collaboration between Elsevier and the FDA will present an algorithm for the accurate prediction of drug-induced liver injury. Drug Target Review investigates the benefits this toxicology project will bring to the drug discovery industry.
Recent research into why autoimmune disorders affect women four times more frequently than men has revealed several novel therapeutic targets that may lead to the development of future treatments.